Evogene Competitors

Stocks . Israel . 
Stock . Evogene
EVGN Stock  ILA 606.00  32.00  5.02%   
Evogene competes with Netz Hotels, Migdal Insurance, Harel Insurance, Menora Miv, and Clal Insurance; as well as few others. The company operates under Biotechnology sector and is part of Health Care industry. Analyzing Evogene competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Evogene to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Evogene Correlation with its peers.
For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Evogene competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
601.09606.00610.91
Details
Intrinsic
Valuation
LowRealHigh
576.85581.76666.60
Details
Naive
Forecast
LowNextHigh
606.99611.89616.80
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
586.50616.67646.84
Details

Evogene Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Evogene and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Evogene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Evogene does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CLIS
+ 0.97
MGDL
CLIS
+ 0.97
HARL
PHOE
+ 0.97
MMHD
HARL
+ 0.95
MGDL
MMHD
+ 0.93
MGDL
PHOE
+ 0.93
MGDL
  
High negative correlations   
XTLB
- 0.93
MGDL
XTLB
- 0.86
CLIS
BMDX
- 0.85
XTLB
XTLB
- 0.85
PHOE
XTLB
- 0.83
MMHD
XTLB
- 0.82
HARL

Risk-Adjusted Indicators

There is a big difference between Evogene Stock performing well and Evogene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Evogene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NZHT  2.83  0.08  0.00  0.27  2.98 
(3.73)
 6.55 
(5.50)
 22.43 
MGDL  1.39  0.47  0.22 (3.99) 1.10 
(1.67)
 3.81 
(2.07)
 7.52 
HARL  1.60  0.34  0.09  13.86  2.06 
(1.66)
 3.33 
(2.74)
 13.90 
MMHD  1.63  0.40  0.16  3.64  1.48 
(1.90)
 3.02 
(2.67)
 8.51 
CLIS  1.51  0.30  0.11  1.79  1.48 
(1.66)
 3.77 
(2.57)
 7.47 
PHOE  1.19  0.31  0.14  1.00  1.09 
(1.46)
 2.84 
(2.08)
 9.91 
XTLB  3.79 (0.29) 0.00  8.66  0.00 
 0.00 
 9.23 
(8.18)
 41.17 
ISOP-L  2.01  0.34  0.06 (0.91) 2.32 
(2.44)
 5.05 
(5.33)
 17.11 
BMDX  3.29  0.21  0.03  0.68  4.37 
(3.36)
 7.60 
(7.31)
 23.26 
SVRT  3.49 (0.45) 0.00 (0.02) 0.00 
 0.00 
 6.31 
(8.04)
 48.17 
All Fundamental Data

Evogene Competitive Analysis

The better you understand Evogene competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Evogene's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Evogene's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EVGN NZHT MGDL HARL MMHD CLIS PHOE XTLB ISOP-L BMDX
 5.02 
 606.00 
Evogene
 3.92 
 31.80 
Netz
 3.25 
 631.40 
Migdal
 1.20 
 4,200 
Harel
 2.69 
 13,040 
Menora
 2.60 
 7,500 
Clal
 2.23 
 4,654 
Phoenix
 3.08 
 6.70 
XTL
 0.25 
 79.50 
Israel
 2.56 
 19,200 
Biomedix
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Relatively risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Insignificant
Very Strong
Good
Strong
Solid
Solid
Very Weak
OK
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Low
Low
Low
Low
Low
Quite High
Below Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Cautious Hold
Strong Hold
Strong Buy
Strong Buy
Strong Buy
Strong Sell
Strong Sell
Strong Sell
Current Ratio
12.74
969.52
483.81
259.4
225.32
146.62
70.54
51.07
33.54
30.06
Net Asset
76.3 M
86.92 M
204.16 B
137.67 B
66.79 B
145.51 B
143.58 B
N/A
8.21 M
N/A
Profit Margin
N/A
N/A
0.0799
0.0638
0.094
0.0403
0.14
N/A
N/A
N/A
EBITDA
(26.78 M)
N/A
1.73 B
1.37 B
1.04 B
804.93 M
2.44 B
(940 K)
(1.35 M)
(1.46 M)
Operating Margin
-24.02
N/A
0.14
0.0834
0.14
0.0722
0.2
N/A
-6.65
N/A
Current Valuation
8.8 M
N/A
(13.27 B)
11.04 B
4.77 B
(3.97 B)
(4.8 B)
61.84 M
10.02 M
14.72 M
Price To Book
0.93
N/A
0.61
0.82
0.77
0.57
0.98
N/A
1.17
361.86
Retained Earnings
(90 M)
(77 M)
4.09 B
4.26 B
2.45 B
2.73 B
N/A
N/A
(26 M)
(181 M)
Current Asset
95 M
3 M
90.41 B
16.57 B
5.44 B
62.68 B
N/A
N/A
21 M
9 M
Five Year Return
N/A
N/A
4.56
5.78
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.9
0.3
1.06
0.52
0.66
0.82
0.5
1.03
1.57
1.21
Number Of Employees
133
18
4.57 K
4.94 K
3.19 K
4.3 K
406
3
3
8
Shares Outstanding
41.22 M
N/A
1.05 B
211.09 M
61.88 M
74.06 M
252.54 M
514.21 M
41.01 M
2.07 M
Cash Flow From Operations
(24.72 M)
(2.64 M)
7.12 B
1.19 B
1.24 B
7.09 B
4.55 B
(1.05 M)
(1.44 M)
(1.62 M)
Annual Yield
N/A
N/A
0.0099
0.0559
0.0102
N/A
0.0822
N/A
N/A
N/A
Total Debt
2.39 M
N/A
5.33 B
6.53 B
1.75 B
4.28 B
5.48 B
N/A
75 K
N/A
Return On Equity
-0.63
N/A
0.12
0.11
0.11
0.0562
0.18
0.38
-0.14
-21.76
Z Score
29.8
N/A
N/A
0.6
1.2
0.6
0.6
N/A
0.6
-26.8
Return On Asset
-0.28
N/A
0.0052
0.0058
0.0087
0.0034
0.0103
-0.1
-0.0899
-14.0
Book Value Per Share
0.74
1.13
7.34
38.42
92.08
107.69
38.47
0.009
0.15
4.98
Current Liabilities
6 M
86 M
130 M
1.48 B
57 M
255 M
N/A
N/A
N/A
N/A
Total Asset
76.3 M
86.92 M
204.16 B
137.67 B
66.79 B
145.51 B
143.58 B
N/A
8.21 M
9 M
Debt To Equity
0.031
60.4
75.4
60.0
44.0
0.64
63.2
N/A
0.008
N/A
Target Price
5.0
N/A
4.8
19.8
42.0
75.0
43.5
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
0.045
1.88
0.81
N/A
2.31
N/A
N/A
N/A
Shares Owned By Institutions
3.37
N/A
3.97
12.33
8.56
23.2
14.6
N/A
10.27
N/A
Market Capitalization
121.59 M
51.84 M
4.49 B
7.18 B
4.82 B
4.59 B
9.53 B
236.53 K
362.49 K
37.28 M
Price To Earning
N/A
869.05
829.07
759.38
602.29
671.42
798.36
558.33
N/A
-545.45
Price To Sales
73.01
N/A
0.38
0.44
0.66
0.42
0.8
N/A
1.76
N/A
Net Income
(27.79 M)
(19.82 M)
1.35 B
1.21 B
685.34 M
1.08 B
1.96 B
435 K
(1.41 M)
(1.36 M)
Earnings Per Share
-0.72
-0.04
0.87
4.43
9.8
6.05
6.35
N/A
-0.028
-1.1
Shares Owned By Insiders
3.58
N/A
64.2
47.5
66.03
20.2
33.35
16.2
10.29
N/A
Revenue
930 K
N/A
36.68 B
27.49 B
12.99 B
25.06 B
28.27 B
N/A
N/A
2 K
Working Capital
89 M
(83 M)
90.28 B
15.09 B
5.38 B
62.43 B
N/A
N/A
21 M
9 M
Cash And Equivalents
65.36 M
57.78 M
116.96 B
14.65 B
17.45 B
90.83 B
69.87 B
5.06 M
7.9 M
5.71 M
Cash Per Share
1.61
0.75
98.8
68.56
275.46
N/A
272.82
0.01
0.19
5.1
Gross Profit
163 K
N/A
3.45 B
2.94 B
2.13 B
2.91 B
4.5 B
N/A
(140 K)
(39 K)
Day Typical Price
616.9
31.4
629.93
4190.0
13190.0
7550.33
4681.67
6.6
79.0
19070.0
Accumulation Distribution
0.0512
0.0377
0.0371
0.0231
0.0334
0.0323
0.0271
0.0735
0.0189
0.0508
Market Facilitation Index
32.7
1.2
23.8
98.0
450.0
249.0
129.0
0.5
1.5
990.0
Daily Balance Of Power
(0.98)
1.0
(0.89)
(0.52)
(0.80)
(0.80)
(0.82)
0.4
(0.13)
0.4848
Period Momentum Indicator
(32.00)
1.2
(21.20)
(51.00)
(360.00)
(200.00)
(106.00)
0.2
(0.20)
480.0
Rate Of Daily Change
0.95
1.04
0.97
0.99
0.97
0.97
0.98
1.03
1.0
1.03
Day Median Price
622.35
31.2
629.2
4185.0
13265.0
7575.5
4695.5
6.55
78.75
19005.0
Price Action Indicator
(32.35)
1.2
(8.40)
(10.50)
(405.00)
(175.50)
(94.50)
0.25
0.65
435.0
Relative Strength Index
20.4
70.45
96.2
61.76
53.2
80.73
39.82
35.36
67.54
32.32
Coefficient Of Variation
(260.33)
2669.48
382.07
610.59
452.52
580.95
460.05
(1,993)
935.79
1669.99
Mean Deviation
3.31
2.83
1.39
1.6
1.63
1.51
1.19
3.79
2.01
3.29
Jensen Alpha
(1.82)
0.0767
0.4674
0.3421
0.4031
0.298
0.3104
(0.29)
0.3397
0.2101
Total Risk Alpha
(2.64)
(0.49)
0.1747
0.0036
0.1127
0.018
0.09
(1.21)
(0.16)
(0.44)
Sortino Ratio
N/A
0.0049
0.2173
0.0936
0.1618
0.1087
0.1405
N/A
0.0612
0.0277
Downside Variance
N/A
12.56
2.35
5.75
3.35
3.34
2.73
N/A
8.57
23.69
Standard Deviation
4.85
3.96
1.77
2.17
1.93
1.91
1.67
5.76
2.9
4.43
Kurtosis
5.19
2.9
(0.06)
2.77
(0.76)
(0.12)
2.47
7.28
1.66
0.6919
Potential Upside
5.18
6.55
3.81
3.33
3.02
3.77
2.84
9.23
5.05
7.6
Treynor Ratio
4.75
0.2712
(3.99)
13.86
3.64
1.79
1.0
8.66
(0.91)
0.679
Maximum Drawdown
30.28
22.43
7.52
13.9
8.51
7.47
9.91
41.17
17.11
23.26
Variance
23.5
15.67
3.14
4.7
3.73
3.66
2.79
33.13
8.41
19.66
Market Risk Adjusted Performance
4.76
0.2812
(3.98)
13.87
3.65
1.8
1.01
8.67
(0.90)
0.689
Risk Adjusted Performance
(0.29)
0.0368
0.2064
0.1321
0.1755
0.138
0.1721
(0.03)
0.0893
0.0542
Skewness
1.12
1.16
0.2051
(0.66)
(0.08)
0.2472
0.5038
(1.21)
0.1791
(0.35)
Semi Deviation
N/A
2.98
1.1
2.06
1.48
1.48
1.09
N/A
2.32
4.37
Information Ratio
(0.41)
0.0044
0.1879
0.1035
0.1533
0.1038
0.139
(0.07)
0.0618
0.0304
Value At Risk
(9.63)
(5.50)
(2.07)
(2.74)
(2.67)
(2.57)
(2.08)
(8.18)
(5.33)
(7.31)
Expected Short fall
N/A
(3.73)
(1.67)
(1.66)
(1.90)
(1.66)
(1.46)
N/A
(2.44)
(3.36)
Downside Deviation
N/A
3.54
1.53
2.4
1.83
1.83
1.65
N/A
2.93
4.87
Semi Variance
N/A
8.86
1.22
4.24
2.18
2.2
1.19
N/A
5.4
19.11

Evogene Competition Performance Charts

Five steps to successful analysis of Evogene Competition

Evogene's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Evogene in relation to its competition. Evogene's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Evogene in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Evogene's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Evogene, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Evogene position

In addition to having Evogene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Furniture Thematic Idea Now

Furniture
Furniture Theme
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Evogene Stock

When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
How To Invest In Evogene
Details
Is Evogene Stock a good investment?
Details
What is Evogene's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Evogene Correlation with its peers.
For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY